Loading…
Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient
The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell
Saved in:
| Published in: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2021-02, Vol.27 (2), p.387-389 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c446t-e35961c0e17624e4c26b358981e6982cec453ef66d6a32d9d0b58be75293a8823 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c446t-e35961c0e17624e4c26b358981e6982cec453ef66d6a32d9d0b58be75293a8823 |
| container_end_page | 389 |
| container_issue | 2 |
| container_start_page | 387 |
| container_title | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| container_volume | 27 |
| creator | Nakajima, Yukiko Ogai, Asuca Furukawa, Karin Arai, Ryosuke Anan, Ryusuke Nakano, Yasushi Kurihara, Yuko Shimizu, Hideaki Misaki, Takako Okabe, Nobuhiko |
| description | The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell |
| doi_str_mv | 10.1016/j.jiac.2020.12.001 |
| format | article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7836222</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1341321X20304360</els_id><sourcerecordid>S1341321X20304360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-e35961c0e17624e4c26b358981e6982cec453ef66d6a32d9d0b58be75293a8823</originalsourceid><addsrcrecordid>eNp9kN1KwzAUx4Mobk5fwAvpC3Tmo01TEGEMp8JAcSrehSw521LWpiTdwLc3Yzr0xquEnP_HyQ-hS4KHBBN-XQ0rq_SQYhof6BBjcoT6JGNFWhQCH8c7y0jKKPnoobMQqigociFOUY8xRgVheR9Nnr1bu2YJJtlar9ZJWIExtlkmbpHMRi-zdOzeU5rYJlFNYut60zjt6ta72oZoalVnoenO0clCrQNcfJ8D9Da5ex0_pNOn-8fxaJrqLONdCiwvOdEYSMFpBpmmfM5yUQoCvBRUg85yBgvODVeMmtLgeS7mUOS0ZEoIygbodp_bbuY1GB2r49Ky9bZW_lM6ZeXfSWNXcum2shCMU7oLoPsA7V0IHhYHL8FyR1VWckdV7qhKQmWEFk1Xv1sPlh-MUXCzF0D8-9aCl0FHLBqM9aA7aZz9L_8L_UqI3A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient</title><source>Elsevier</source><creator>Nakajima, Yukiko ; Ogai, Asuca ; Furukawa, Karin ; Arai, Ryosuke ; Anan, Ryusuke ; Nakano, Yasushi ; Kurihara, Yuko ; Shimizu, Hideaki ; Misaki, Takako ; Okabe, Nobuhiko</creator><creatorcontrib>Nakajima, Yukiko ; Ogai, Asuca ; Furukawa, Karin ; Arai, Ryosuke ; Anan, Ryusuke ; Nakano, Yasushi ; Kurihara, Yuko ; Shimizu, Hideaki ; Misaki, Takako ; Okabe, Nobuhiko</creatorcontrib><description>The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1016/j.jiac.2020.12.001</identifier><identifier>PMID: 33328135</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Antiviral Agents - therapeutic use ; Bendamustine ; Case Report ; COVID-19 - complications ; COVID-19 - immunology ; COVID-19 - therapy ; COVID-19 - virology ; Follicular lymphoma ; Humans ; Immunocompromised Host ; Immunocompromised state ; Lymphoma - complications ; Lymphoma - virology ; Male ; Middle Aged ; Nasopharynx - virology ; Reverse Transcriptase Polymerase Chain Reaction - methods ; RNA, Viral - analysis ; SARS-CoV-2 - isolation & purification ; SARS-CoV-2 PCR ; Time Factors ; Treatment Outcome ; Viral replication ; Virus Shedding</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021-02, Vol.27 (2), p.387-389</ispartof><rights>2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases</rights><rights>Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><rights>2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-e35961c0e17624e4c26b358981e6982cec453ef66d6a32d9d0b58be75293a8823</citedby><cites>FETCH-LOGICAL-c446t-e35961c0e17624e4c26b358981e6982cec453ef66d6a32d9d0b58be75293a8823</cites><orcidid>0000-0003-4039-3593 ; 0000-0002-5665-1676</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33328135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakajima, Yukiko</creatorcontrib><creatorcontrib>Ogai, Asuca</creatorcontrib><creatorcontrib>Furukawa, Karin</creatorcontrib><creatorcontrib>Arai, Ryosuke</creatorcontrib><creatorcontrib>Anan, Ryusuke</creatorcontrib><creatorcontrib>Nakano, Yasushi</creatorcontrib><creatorcontrib>Kurihara, Yuko</creatorcontrib><creatorcontrib>Shimizu, Hideaki</creatorcontrib><creatorcontrib>Misaki, Takako</creatorcontrib><creatorcontrib>Okabe, Nobuhiko</creatorcontrib><title>Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><description>The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Bendamustine</subject><subject>Case Report</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - therapy</subject><subject>COVID-19 - virology</subject><subject>Follicular lymphoma</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised state</subject><subject>Lymphoma - complications</subject><subject>Lymphoma - virology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nasopharynx - virology</subject><subject>Reverse Transcriptase Polymerase Chain Reaction - methods</subject><subject>RNA, Viral - analysis</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>SARS-CoV-2 PCR</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Viral replication</subject><subject>Virus Shedding</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kN1KwzAUx4Mobk5fwAvpC3Tmo01TEGEMp8JAcSrehSw521LWpiTdwLc3Yzr0xquEnP_HyQ-hS4KHBBN-XQ0rq_SQYhof6BBjcoT6JGNFWhQCH8c7y0jKKPnoobMQqigociFOUY8xRgVheR9Nnr1bu2YJJtlar9ZJWIExtlkmbpHMRi-zdOzeU5rYJlFNYut60zjt6ta72oZoalVnoenO0clCrQNcfJ8D9Da5ex0_pNOn-8fxaJrqLONdCiwvOdEYSMFpBpmmfM5yUQoCvBRUg85yBgvODVeMmtLgeS7mUOS0ZEoIygbodp_bbuY1GB2r49Ky9bZW_lM6ZeXfSWNXcum2shCMU7oLoPsA7V0IHhYHL8FyR1VWckdV7qhKQmWEFk1Xv1sPlh-MUXCzF0D8-9aCl0FHLBqM9aA7aZz9L_8L_UqI3A</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Nakajima, Yukiko</creator><creator>Ogai, Asuca</creator><creator>Furukawa, Karin</creator><creator>Arai, Ryosuke</creator><creator>Anan, Ryusuke</creator><creator>Nakano, Yasushi</creator><creator>Kurihara, Yuko</creator><creator>Shimizu, Hideaki</creator><creator>Misaki, Takako</creator><creator>Okabe, Nobuhiko</creator><general>Elsevier Ltd</general><general>Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4039-3593</orcidid><orcidid>https://orcid.org/0000-0002-5665-1676</orcidid></search><sort><creationdate>20210201</creationdate><title>Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient</title><author>Nakajima, Yukiko ; Ogai, Asuca ; Furukawa, Karin ; Arai, Ryosuke ; Anan, Ryusuke ; Nakano, Yasushi ; Kurihara, Yuko ; Shimizu, Hideaki ; Misaki, Takako ; Okabe, Nobuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-e35961c0e17624e4c26b358981e6982cec453ef66d6a32d9d0b58be75293a8823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Bendamustine</topic><topic>Case Report</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - therapy</topic><topic>COVID-19 - virology</topic><topic>Follicular lymphoma</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised state</topic><topic>Lymphoma - complications</topic><topic>Lymphoma - virology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nasopharynx - virology</topic><topic>Reverse Transcriptase Polymerase Chain Reaction - methods</topic><topic>RNA, Viral - analysis</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>SARS-CoV-2 PCR</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Viral replication</topic><topic>Virus Shedding</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakajima, Yukiko</creatorcontrib><creatorcontrib>Ogai, Asuca</creatorcontrib><creatorcontrib>Furukawa, Karin</creatorcontrib><creatorcontrib>Arai, Ryosuke</creatorcontrib><creatorcontrib>Anan, Ryusuke</creatorcontrib><creatorcontrib>Nakano, Yasushi</creatorcontrib><creatorcontrib>Kurihara, Yuko</creatorcontrib><creatorcontrib>Shimizu, Hideaki</creatorcontrib><creatorcontrib>Misaki, Takako</creatorcontrib><creatorcontrib>Okabe, Nobuhiko</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakajima, Yukiko</au><au>Ogai, Asuca</au><au>Furukawa, Karin</au><au>Arai, Ryosuke</au><au>Anan, Ryusuke</au><au>Nakano, Yasushi</au><au>Kurihara, Yuko</au><au>Shimizu, Hideaki</au><au>Misaki, Takako</au><au>Okabe, Nobuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><addtitle>J Infect Chemother</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>27</volume><issue>2</issue><spage>387</spage><epage>389</epage><pages>387-389</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>33328135</pmid><doi>10.1016/j.jiac.2020.12.001</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-4039-3593</orcidid><orcidid>https://orcid.org/0000-0002-5665-1676</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-321X |
| ispartof | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021-02, Vol.27 (2), p.387-389 |
| issn | 1341-321X 1437-7780 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7836222 |
| source | Elsevier |
| subjects | Antiviral Agents - therapeutic use Bendamustine Case Report COVID-19 - complications COVID-19 - immunology COVID-19 - therapy COVID-19 - virology Follicular lymphoma Humans Immunocompromised Host Immunocompromised state Lymphoma - complications Lymphoma - virology Male Middle Aged Nasopharynx - virology Reverse Transcriptase Polymerase Chain Reaction - methods RNA, Viral - analysis SARS-CoV-2 - isolation & purification SARS-CoV-2 PCR Time Factors Treatment Outcome Viral replication Virus Shedding |
| title | Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A32%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20viral%20shedding%20of%20SARS-CoV-2%20in%20an%20immunocompromised%20patient&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Nakajima,%20Yukiko&rft.date=2021-02-01&rft.volume=27&rft.issue=2&rft.spage=387&rft.epage=389&rft.pages=387-389&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1016/j.jiac.2020.12.001&rft_dat=%3Celsevier_pubme%3ES1341321X20304360%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-e35961c0e17624e4c26b358981e6982cec453ef66d6a32d9d0b58be75293a8823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33328135&rfr_iscdi=true |